What are the target capillary blood glucose ranges for hospitalized patients and how should insulin be administered in critical and non‑critical settings?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Target Blood Glucose and Insulin Administration in Hospitalized Patients

For both critically ill and non-critically ill hospitalized patients, initiate insulin therapy when blood glucose persistently exceeds 180 mg/dL (checked on two occasions), and target a glucose range of 140-180 mg/dL (7.8-10.0 mmol/L) to reduce mortality while avoiding the significant hypoglycemia risk associated with tighter control. 1

Critical Evidence: Why Not Tighter Control?

The landmark NICE-SUGAR trial fundamentally changed inpatient glycemic management. While earlier studies suggested intensive control (80-110 mg/dL) reduced mortality, NICE-SUGAR demonstrated that tight glycemic management actually increased mortality (27.5% vs. 25%) with 10- to 15-fold higher rates of hypoglycemia compared to moderate targets. 1 This finding is supported by multiple meta-analyses showing tight control increases both mortality and hypoglycemia rates. 1

Glycemic Targets by Clinical Setting

Critically Ill Patients (ICU)

  • Initiation threshold: ≥180 mg/dL on two occasions 1, 2
  • Target range: 140-180 mg/dL (7.8-10.0 mmol/L) 1, 3
  • Selected patients only: 110-140 mg/dL (6.1-7.8 mmol/L) may be appropriate for critically ill post-surgical patients or cardiac surgery patients, only if achievable without significant hypoglycemia 1

Non-Critically Ill Patients

  • Initiation threshold: ≥180 mg/dL on two occasions 1, 4
  • Target range: 100-180 mg/dL (5.6-10.0 mmol/L) for most patients 1
  • Premeal targets: Generally <140 mg/dL (7.8 mmol/L) 5
  • Random glucose: <180 mg/dL (10.0 mmol/L) 5

Important caveat: Fasting glucose levels <100 mg/dL predict hypoglycemia within the next 24 hours, so avoid overly aggressive lowering. 1

Insulin Administration Methods

Critical Care Setting

Use intravenous insulin infusion exclusively 6, 2, 7

  • Validated protocols required that demonstrate efficacy and safety 5
  • Glucose monitoring every 30 minutes to 2 hours during IV insulin 1, 6
  • Arterial blood preferred over capillary for point-of-care testing if arterial catheter present 3

Non-Critical Care Setting

Use scheduled subcutaneous basal-bolus insulin regimen 8, 4

For Patients Eating Regular Meals:

  • Basal insulin: 50% of total daily dose given as glargine (once daily) or detemir/NPH (once or twice daily) 8
  • Prandial insulin: 50% of total daily dose divided equally before each meal (rapid-acting analog) 8
  • Correction insulin: Added to scheduled doses using standardized scales 8
  • Hold prandial insulin if patient cannot eat 8

Calculating Starting Dose:

  • 0.2-0.3 units/kg/day for patients ≥70 years old OR glomerular filtration rate <60 mL/min 8
  • 0.4 units/kg/day for blood glucose 140-200 mg/dL 8
  • 0.5 units/kg/day for blood glucose 201-400 mg/dL 8

For Patients NPO or Not Eating:

  • Basal insulin alone with correction doses using rapid-acting analog every 4 hours OR regular insulin every 6 hours 8
  • Start with insulin-sensitive column for elderly, those not eating, or impaired renal function 8
  • Start with insulin-resistant column for patients on corticosteroids or previously requiring >80 units/day 8

Glucose Monitoring Frequency

Eating Patients:

  • Check point-of-care glucose before each meal and at bedtime 1, 6

NPO or Continuous Feeding:

  • Check glucose every 4-6 hours 1

IV Insulin:

  • Check glucose every 30 minutes to 2 hours 1, 6

Critical Pitfalls to Avoid

Never use sliding-scale insulin alone as primary therapy. This approach results in 3-fold increased risk of hyperglycemia (>200 mg/dL) and causes undesirable glucose variability. 8 Sliding-scale should only be used for patients whose glucose is in target range most of the time and only occasionally exceeds it. 6

Discontinue oral diabetes medications and non-insulin injectables upon hospital admission. 8 These agents have contraindications in many hospitalized patients and delay achievement of glycemic targets, potentially worsening outcomes. 8

Avoid targeting glucose <110 mg/dL. This significantly increases hypoglycemia risk without mortality benefit and may actually increase mortality. 1, 2

Special Populations

Terminally Ill Patients:

  • Glycemic levels >250 mg/dL (13.9 mmol/L) may be acceptable 1
  • Use less aggressive insulin regimens to minimize glucosuria, dehydration, and electrolyte disturbances 1

Patients on Corticosteroids:

  • Expect insulin resistance; start at higher doses 8
  • Consider NPH insulin for corticosteroid-induced hyperglycemia 9

Patients on TPN:

  • Add regular human insulin directly to TPN solution 9

Transition Considerations

When transitioning from IV to subcutaneous insulin, use a proactive scheduled regimen with basal, nutritional/prandial, and correctional components rather than reactive sliding-scale approaches. 6 This prevents the dangerous glucose excursions that occur with inadequate transition planning.

The evidence overwhelmingly supports moderate glycemic targets over intensive control, prioritizing avoidance of hypoglycemia while preventing extreme hyperglycemia—a balance that optimizes mortality and morbidity outcomes in real-world hospital practice.

References

6
Guideline

american association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2022

9
Research

Current Recommendations for Insulin Therapy in the Hospitalized Patient.

Critical care nursing clinics of North America, 2025

Related Questions

What is the appropriate management for a patient whose blood glucose was 404 mg/dL before receiving insulin?
What is the appropriate management for a diabetic patient with a blood glucose of 37 mg/dL?
What is the target blood glucose range for adult intensive care unit (ICU) patients, including recommendations for non‑diabetic and diabetic individuals?
For an outpatient with a blood glucose of 492 mg/dL, what rapid‑acting and basal insulin types and dosing should be used?
How should I manage a patient with a blood glucose of 568 mg/dL after a 12‑unit insulin dose given in the office?
Why is muscle tone reduced during acute neuronal shock in a cerebrovascular accident (CVA)?
What is the immediate management of a chronic alcoholic patient presenting with melena, SpO₂ 100%, mild tachycardia, and acute hypotension (blood pressure dropping from 150/90 to 90/50)?
What is a mucinous cystic neoplasm?
What is the appropriate treatment for an acitrom‑induced INR of 6.5?
Do mural nodules in a pancreatic mucinous cystic neoplasm indicate malignancy?
In an adult with type 2 diabetes, HbA1c 7.2 % and random glucose 160 mg/dL, can a triple oral regimen of dapagliflozin 10 mg daily, sitagliptin 100 mg daily, and metformin 1000 mg daily be prescribed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.